Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) The effects of resveratrol on glycemic control and cardiometabolic parameters in...
Journal Information
Vol. 158. Issue 12.
Pages 576-585 (June 2022)
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 158. Issue 12.
Pages 576-585 (June 2022)
Original article
The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis
Efectos del resveratrol sobre el control glucémico y los parámetros cardiometabólicos en pacientes con diabetes mellitus de tipo 2: una revisión sistemática y un metaanálisis
Visits
...
Ibrahim A. Abdelhaleema,d,
Corresponding author
, Aml M. Brakata,d, Hoda M. Adayelb,d, Moamen M. Aslaa,d, Marwa A. Rizka,d, Aya Y. Aboalfetohc,d
a Faculty of Medicine, Zagazig University, Zagazig City, Sharkia 44519, Egypt
b Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt
c Research and Development Department, Egyptian International Pharmaceutical Industries Company – EPICO, 10th of Ramadan City, Sharkia 44634, Egypt
d International Medical Research Association IMedRA, Egypt
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (7)
Show moreShow less
Tables (1)
Table 1. The characteristics of the included studies.
Additional material (1)
Abstract
Background

Type 2 diabetes mellitus (T2DM) is a progressive meta-inflammatory disorder, which induce micro and macrovascular complications. Resveratrol is a nutraceutical known to have antioxidant and anti-inflammatory properties. It improves insulin resistance; however, no clear evidence regarding its effects in patients with T2DM.

Objectives

We aimed to evaluate the efficacy and the safety of oral resveratrol supplementation in type 2 diabetic patients concerning dose and duration.

Methods

We searched PubMed, Cochrane Library, Scopus, WOS, Wiley, and Google Scholar for RCTs evaluating the efficacy and safety of resveratrol on patients with T2DM. We screened the studies for the eligibility criteria, performed the quality assessment, extracted the studies’ characteristics, baseline, and outcome data of interest, and finally conducted the meta-analysis using RevManV5.3.

Results

This systematic review and meta-analysis, including 17 RCTs with total 871 patients with T2DM, showed that resveratrol was superior to placebo on fasting blood glucose (FBG) and total cholesterol (TC) with doses ≥500mg {MD=−13.34, 95%CI [−22.73, −3.95], P=0.005}, {MD=−5.64, 95%CI [−6.95, −4.33], P<0.00001} respectively. Moreover, it improved HbA1c at three months {MD=−0.41, 95%CI [−0.65, −0.16], P=0.001 and systolic blood pressure {MD: −7.91, 95%CI [−10.44, −5.37], P<0.00001}.

Conclusion

We concluded that resveratrol beneficially modulates glycemic control as well as cardiometabolic parameters in patients with T2DM.

Keywords:
T2DM
Resveratrol
Glycemic control
Cardiometabolic parameters
Meta-analysis
Resumen
Fundamento

La diabetes mellitus de tipo 2 (DM2) es un trastorno metainflamatorio progresivo que induce complicaciones micro- y macrovasculares. El resveratrol es un nutracéutico con propiedades antioxidantes y antiinflamatorias que, además, disminuye la resistencia a la insulina; sin embargo, no hay evidencia clara sobre sus efectos en pacientes con DM2.

Objetivos

Evaluar la eficacia y la seguridad de la suplementación con resveratrol oral en pacientes con DM2 respecto a la dosis y la duración.

Método

Se realizaron búsquedas en PubMed, Cochrane Library, Scopus, WOS, Wiley y Google Scholar en busca de ECA que evaluaran la eficacia y seguridad del resveratrol en pacientes con DM2. Se revisaron los estudios para determinar los criterios de elegibilidad, se hizo la evaluación de la calidad, se extrajeron las características de los estudios, los datos iniciales y los resultados de interés y, finalmente, se realizó el metaanálisis con RevManV5.3.

Resultados

Esta revisión sistemática y metaanálisis, que incluyó 17 ECA con un total de 871 pacientes con DM2, mostró que el resveratrol fue superior al placebo en la glucemia en ayunas y el colesterol total con dosis ≥500mg (MD=−13,34; IC 95%: [−22,73; −3,95]; p=0,005 y MD=−5,64; IC 95%: [−6,95; −4,33]; p<0,00001), respectivamente. Además, mejoró la HbA1c a los 3 meses (DM=−0,41; IC 95%: [−0,65; −0,16]; p=0,001) y la presión arterial sistólica (DM: −7,91; IC 95%: [−10,44; −5,37]; p<0,00001).

Conclusión

El resveratrol contribuye a mejorar el control glucémico, además de los parámetros cardiometabólicos, en pacientes con DM2.

Palabras clave:
DM2
Resveratrol
Control glucémico
Parámetros cardiometabólicos
Metaanálisis

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
Supplemental materials
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos